Peptide Sequencing Strategies
In 1953 Frederick Sanger announced the complete amino acid sequence of bovine insulin. This was the first protein ever sequenced. It followed eight years of patient chemical detective work. He had no genome to consult and no algorithm to lean on. He had to cut a fifty-one residue chain into small fragments. Each fragment was read by chemical degradation. He then reassembled the puzzle by finding where fragments overlapped. This feat won the first of his two Nobel Prizes. It also founded protein chemistry as a discipline. Every sequencing strategy used since, however automated, descends from that same logic. Break the chain reproducibly, identify each piece, and use overlaps to reconstruct order. Sequencing matters because a protein's function depends entirely on residue order. This order specifies the fold, the active site, and post-translational modifications. It ultimately determines whether an enzyme works, a hormone binds, or a mutation causes disease. Genomic sequencing now predicts most sequences in silico. But direct chemical sequencing remains essential wherever the genome does not tell the whole story. This includes mature proteins after signal-peptide removal, proteolytic processing, and disulfide connectivity. It also includes glycosylation, phosphorylation, and other post-translational chemistry invisible to DNA. Modern proteomics identifies every protein in a cell. It quantifies how they change with disease and maps their modifications. All of this rests on the chemistry described here. The big picture is a three-part toolkit. First, chemical degradation, exemplified by the Edman Degradation, reads a peptide one residue at a time. It works from the N-terminus by exploiting the differential reactivity of the α-amino group. Second, selective cleavage cuts a large protein into overlapping fragments. This includes enzymatic methods (trypsin, chymotrypsin, Glu-C, Lys-C) and chemical methods (cyanogen bromide). The fragments become small enough for Edman chemistry or mass spectrometry. Correctly handling Disulfide Bond Formation and Reduction is a prerequisite before any of this can begin. Third, and now dominant, mass spectrometry-based methods measure fragment masses and gas-phase fragmentation patterns. They read sequence directly from mass differences. This achieves speed and sensitivity that chemical methods cannot match. This article works through the mechanism of Edman chemistry step by step. It covers the logic of specific cleavage and disulfide mapping. It also covers the physics of peptide fragmentation in a mass spectrometer. Together these build toward the same overlap-reconstruction principle Sanger used by hand. Throughout, the chemistry connects back to Peptide Nomenclature and Directionality for reading fragment order. It also connects to the Acid-Base Chemistry of Ionizable Side Chains. This governs ionization behind electrospray and MALDI ionization efficiency.
- Edman degradation removes one N-terminal residue at a time as a PTH-amino acid, via phenylisothiocyanate coupling, acid-catalyzed cyclization, and rearrangement — without cleaving the rest of the chain.
- Endopeptidases with narrow specificity (trypsin: after Lys/Arg not before Pro; chymotrypsin: after aromatics) generate predictable, overlapping fragments for reconstruction.
- Disulfides must be reduced (DTT/TCEP) and alkylated (iodoacetamide) before sequencing, or mapped separately by non-reducing/reducing diagonal electrophoresis or comparative MS.
- Tandem MS (MS/MS) fragments peptide ions along the backbone, producing b-ions and y-ions whose mass differences directly give residue identity.
- Overlapping peptide sets from two different proteases (or CNBr) resolve the unique full-length order, exactly as Sanger's insulin work did in the 1950s.
- De novo MS sequencing and database (peptide mass fingerprinting) approaches are complementary: one reads sequence from scratch, the other matches against predicted digests.
- Key idea: every sequencing strategy is variation on cut reproducibly, measure each piece, and use overlaps to fix a unique order.
Where this lives today
Modern clinical and pharmaceutical proteomics runs almost entirely on liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS): a complex protein mixture (a cell lysate, a plasma sample, a therapeutic antibody digest) is digested with trypsin, separated by reversed-phase chromatography, and each eluting peptide is fragmented and matched by database search software (e.g., Mascot, Sequest-type algorithms) against predicted tryptic peptides from a genome-derived protein database — turning Sanger's decade-long manual insulin project into a process that can characterize thousands of proteins from a single sample in hours. Edman degradation, though largely displaced for large-scale discovery work, remains the gold-standard confirmatory method for verifying the N-terminal sequence of a manufactured therapeutic protein or antibody, checking for correct signal-peptide cleavage, and detecting N-terminal heterogeneity (e.g., partial loss of the initiator Met or unwanted N-terminal truncation) that mass spectrometry alone might not flag as clearly. Disulfide mapping by MS (comparing tryptic digests before and after reduction, watching which fragment masses shift) is now routine quality control for biologic drugs (insulin analogs, monoclonal antibodies, engineered cytokines), where a single mispaired or missing disulfide can abolish activity or trigger immunogenicity; this same logic — non-reduced vs. reduced comparison — traces directly back to how Sanger first established insulin's A-chain/B-chain disulfide connectivity. Top-down mass spectrometry, fragmenting whole intact proteins in the gas phase without prior proteolytic digestion, is now used to characterize proteoforms carrying combinations of post-translational modifications that would be scattered across many separate tryptic peptides and hence invisible as a single coherent pattern in conventional bottom-up work — a capability directly relevant to the modifications catalogued under Non-Standard and Modified Amino Acids. Forensic and archaeological proteomics (paleoproteomics) applies the same MS/MS fragment-ladder logic to degraded ancient protein residues, reading partial sequence from bone collagen or eggshell proteins thousands to millions of years old, far beyond the reach of DNA preservation.
Ask the tutor: How does high-resolution MS actually resolve near-isobaric residues like Gln and Lys in practice, and what instrument resolving power is needed?
The physical picture — from Edman chemistry to fragment ions
The Edman degradation works because the peptide's α-amino group is a much better nucleophile toward a mild electrophile than any side chain amide, ester, or (once protected) thiol, and because the resulting cyclic thiazolinone is selectively hydrolyzed off the chain under conditions too mild to hydrolyze ordinary peptide bonds. Phenyl isothiocyanate (PITC, Edman's reagent) has an electrophilic central carbon flanked by resonance-stabilized N and S; the peptide's terminal amine attacks that carbon to form a phenylthiocarbamyl (PTC) peptide. Anhydrous acid then triggers an intramolecular cyclization: the sulfur of the PTC group attacks the carbonyl carbon of the first peptide bond, expelling the rest of the chain as an anilinothiazolinone (ATZ) derivative of the terminal residue and leaving the shortened peptide intact with a fresh, exposed α-amine ready for the next cycle. The ATZ-amino acid is then converted, under aqueous acid, to the more stable phenylthiohydantoin (PTH-amino acid), which is identified by chromatography. Endopeptidase cleavage complements this by cutting the protein into pieces small enough (typically under 40–50 residues) for Edman chemistry or MS to read reliably, since Edman degradation efficiency drops with cycle number due to incomplete coupling and side reactions, capping practical reads at roughly 30–60 residues. Trypsin's selectivity comes from an aspartate at the bottom of its S1 specificity pocket that forms a salt bridge with the protonated ε-amino or guanidinium group of Lys or Arg side chains, positioning that residue's carbonyl for nucleophilic attack by the catalytic serine — precisely the Serine Protease Catalytic Triad mechanism, generating cleavage specifically on the carboxyl side of Lys/Arg (except before Pro, which cannot present its imide nitrogen properly for the tetrahedral intermediate collapse). Mass spectrometry sequencing exploits a different physical principle: peptide bonds fragment preferentially in the gas phase along low-energy pathways when a protonated peptide ion is given excess internal energy by collision with an inert gas (collision-induced dissociation, CID). The mobile proton migrates along the backbone and catalyzes amide bond cleavage through a five-membered oxazolone intermediate, splitting the peptide into complementary N-terminal (b-ion) and C-terminal (y-ion) fragments whose mass difference across a cleavage site equals the residue mass of the amino acid at that position — turning a mass spectrum directly into a sequence ladder.
The core ideas — governing relationships
PTH-amino acid identity by retention time. Each cycle of Edman degradation releases one PTH-amino acid, identified chromatographically against known standards:
where: cycle number n corresponds directly to position n counted from the N-terminus of the original peptide, because each cycle removes exactly one residue and leaves the rest of the chain untouched.
Reading: sequential Edman cycles convert the "which residue is where" problem into a chromatography problem, one clean data point per cycle — the fundamental reason Edman chemistry, unlike naive Fmoc-type hydrolysis, can read order at all.
Trypsin cleavage rule. Cleavage occurs on the carboxyl side of Lys or Arg, except when the following residue is Pro:
where: the vertical bar marks the scissile bond; Xaa and Yaa are any residues; the Pro exception arises because proline's cyclic secondary amine cannot adopt the geometry needed for the tetrahedral transition state at the active site.
Reading: the number of tryptic fragments from a protein of N residues is approximately the number of internal Lys/Arg residues not followed by Pro, plus one — this predicts fragment count before any experiment is run.
Peptide fragment mass ladder in MS/MS. For a peptide ion fragmented by CID, the singly protonated b-ion and y-ion series satisfy:
where: is the residue mass (monoisotopic mass of the amino acid minus water) of residue ; is the total number of residues; the accounts for the extra water retained on the C-terminal fragment; the terminal in each is the added proton charge.
Reading: consecutive b-ions (or y-ions) differ in mass by exactly the residue mass of the amino acid between them, so subtracting adjacent peaks in a tandem mass spectrum reads the sequence directly, residue by residue, analogous to reading successive Edman cycles but from a single spectrum instead of dozens of chromatography runs.
Precursor mass and charge state. The mass-to-charge ratio measured by the spectrometer for a precursor ion of neutral monoisotopic mass carrying protons is:
where: is the neutral peptide mass (sum of residue masses plus one water for the free termini), is the number of protons added by ionization (charge state), and Da is the mass of a proton.
Reading: the same peptide appears at different values depending on charge state acquired during electrospray ionization; multiply by and subtract protons to recover the true neutral mass — essential for identifying the peptide before fragmentation is even attempted.
Goal. Show explicitly, with curved arrows in words, why PITC coupling followed by acid treatment cleaves exactly one N-terminal residue and leaves the rest of the peptide chain intact — the central design feature that makes iterative reading possible.
Step 1 — Nucleophilic addition (coupling). The peptide's free α-amino nitrogen, made nucleophilic by its lone pair (and freed of protonation at pH ≈ 9 in the coupling buffer, consistent with the Acid-Base Chemistry of Ionizable Side Chains governing α-amino pK_a ≈ 9–10.6), attacks the electrophilic central carbon of phenyl isothiocyanate, Ph–N=C=S. The C=S π bond electrons shift onto sulfur, generating a thiolate-like intermediate that is reprotonated to give the neutral phenylthiocarbamyl (PTC) adduct: Ph–NH–C(=S)–NH–CHR₁–CO–peptide. Crucially, no other nucleophile in the peptide (backbone amides, most side chains) reacts significantly under these mild, mildly basic conditions — the reaction is chemoselective for the single free α-amine at the N-terminus.
Step 2 — Acid-catalyzed cyclization. Treatment with anhydrous strong acid (commonly trifluoroacetic acid vapor or liquid) protonates the peptide-bond carbonyl oxygen between residue 1 and residue 2, activating that carbonyl carbon toward nucleophilic attack. The thiocarbonyl sulfur of the PTC group, positioned five atoms away, attacks this activated carbonyl carbon intramolecularly. This forms a five-membered ring (2-anilino-5-thiazolinone, "ATZ") fused around residue 1, with a tetrahedral alkoxide-like intermediate at the former peptide carbonyl carbon. That tetrahedral intermediate collapses by kicking out the nitrogen of residue 2 as the leaving group — cleaving the peptide bond between residues 1 and 2. Because the leaving nitrogen is now the new N-terminal amine of the shortened peptide (protonated under the acidic conditions, then liberated on neutralization), the rest of the chain departs intact and undamaged, distinguished from the rest of the protein only by losing one residue.
Step 3 — Rearrangement to the stable PTH derivative. The ATZ-amino acid released in Step 2 is only kinetically stable; it is extracted into an organic solvent (butyl chloride, immiscible with the aqueous peptide phase) and then converted, on mild aqueous acid treatment, to the thermodynamically more stable phenylthiohydantoin (PTH) isomer via ring contraction/rearrangement that relocates the double bond and forms the more stable hydantoin ring system. The PTH-amino acid, bearing the identifying side chain R₁, is then separated and identified by reversed-phase HPLC against known PTH-standards (historically also thin-layer chromatography), typically detected by UV absorbance near 269 nm characteristic of the phenylthiohydantoin chromophore. The shortened peptide, now missing residue 1 and displaying a fresh free α-amine, is carried into the next coupling cycle. Because the extraction into organic solvent removes only the small ATZ/PTH derivative while the peptide (typically less volatile, often anchored to a solid support in automated sequencers) remains in the aqueous/support phase, the cycle can repeat 30–60 times before cumulative incomplete-coupling and side-reaction losses degrade the signal below detectability — this is the practical ceiling on Edman read length, and the reason large proteins must first be fragmented.
Go deeper · Derivation B · 2 minReconstructing sequence from tandem mass spectrometry: the b/y ladder
Goal. Derive how the ladder of b-ions and y-ions in a CID mass spectrum is read to give unambiguous residue-by-residue sequence, using an explicit non-round numeric example built into the logic.
Step 1 — Where fragmentation occurs. Under low-energy collisional activation, a multiply protonated peptide ion collides with inert gas (commonly argon or nitrogen) in the collision cell, converting translational kinetic energy into vibrational energy distributed over the peptide backbone. A mobile proton (one of the ionizing protons, often originally on a basic side chain or the N-terminus) migrates to backbone amide nitrogens. Protonation of an amide nitrogen makes the adjacent carbonyl far more electrophilic; the carbonyl oxygen of the preceding residue's side chain-bearing carbon attacks that carbon intramolecularly, forming a five-membered oxazolone ring and expelling the C-terminal portion of the chain as a neutral amine (later re-protonated in the gas phase if it retains a charge). This is the dominant "amide bond" cleavage pathway and produces two complementary fragment types depending on which portion retains the charge:
Step 2 — Mass bookkeeping. For a peptide of monoisotopic residue masses (each residue mass = free amino acid mass − 18.0106 Da for the water lost in peptide bond formation), the singly charged b-ion containing the first residues has mass:
and the complementary y-ion containing the last residues has mass:
Note the internal consistency check: since the full peptide's neutral mass is , we always have
— the two complementary singly-charged fragment masses sum to the neutral peptide mass plus two proton masses, which is the standard diagnostic used to confirm that two peaks in a spectrum are genuinely a complementary b/y pair rather than coincidental masses.
Step 3 — Reading the ladder. Suppose consecutive b-ions in a spectrum appear at , , and (all singly charged, arbitrary non-round values chosen for illustration). The mass differences are:
Each mass gap between adjacent members of the b-ion (or y-ion) ladder equals a residue mass, and residue masses are essentially all distinct (Leu/Ile at 113.084 Da are isomeric and cannot be distinguished by mass alone; Gln 128.0586 vs Lys 128.0949 differ by only 0.036 Da, resolvable only on high-resolution instruments) — so the ladder can be read almost as directly as an Edman chromatography trace, but from one spectrum rather than dozens of sequential wet-chemistry cycles.
Limiting case check. If a peptide is only two residues long (), there is exactly one possible internal cleavage, giving one b-ion/y-ion pair: (mass of residue 1 + proton) and (mass of residue 2 + water + proton), and exactly as the general formula requires — the shortest possible sanity check on the bookkeeping.
Worked examples
Example 1 (foundational): Reading three Edman cycles by hand. A pentapeptide of unknown sequence is subjected to Edman degradation. HPLC analysis of the PTH-derivatives released after cycles 1, 2, and 3 identifies PTH-Ala, PTH-Gly, and PTH-Ser respectively (in that cycle order); the peptide is known independently (by amino acid analysis after total acid hydrolysis) to contain one each of Ala, Gly, Ser, Leu, Val. Because cycle n releases the residue occupying position n from the N-terminus, the identifications directly give:
The remaining two residues, Leu and Val, must occupy positions 4 and 5, but Edman degradation alone (stopped after 3 cycles here) cannot distinguish their order without a fourth cycle. Suppose cycle 4 gives PTH-Val. Then the full sequence is:
Limiting case check: if instead cycle 1 had released no detectable PTH-amino acid at all, this signals an N-terminally blocked peptide (commonly N-acetylated or pyroglutamate-cyclized in vivo) — a real experimental limiting case in which Edman chemistry fails entirely regardless of how many cycles are attempted, requiring an alternative such as MS/MS or chemical deblocking before sequencing can proceed.
Example 2 (applied): Designing a tryptic digest to distinguish two candidate sequences. A 12-residue peptide hormone candidate has the proposed sequence:
Predict the tryptic fragments (trypsin cleaves C-terminal to Lys/Arg, except when followed by Pro).
Step 1. Scan for Lys and Arg: position 6 is Arg, position 8 is Lys.
Step 2. Check what follows each: position 7 (following Arg-6) is Pro — cleavage is blocked here by the Pro exception. Position 9 (following Lys-8) is Ser — cleavage proceeds normally.
Step 3. The only actual cleavage is after Lys-8. This produces two fragments:
Step 4. Compute Fragment B's monoisotopic mass as a check, using residue masses Ser 87.0320, Trp 186.0793, Asp 115.0269, Ala 71.0371 Da, plus one water (18.0106 Da) for the intact peptide:
If mass spectrometry of the tryptic digest instead shows a fragment at neutral mass 461.19 Da (roughly 16 Da lighter, consistent with Asp→Asn, a common deamidation artifact, or a genuine sequence difference of Asp vs Asn, mass 114.0429 vs 115.0269, a 0.984 Da difference — not 16 Da), this would flag that the proposed sequence needs re-examination; a 16 Da discrepancy more likely indicates a missed oxidation (e.g., Met→Met-sulfoxide, +15.9949 Da) elsewhere, illustrating how mass discrepancies of characteristic sizes point to specific chemical modifications rather than simple sequence errors.
Limiting case check: if the peptide instead had Arg immediately followed by a residue other than Pro at every basic residue, trypsin would cleave after both Arg-6 and Lys-8, producing three fragments instead of two — confirming that the Pro-exception, not some generic rule, is solely responsible for the reduced fragment count here.
Example 3 (exam/competition level): Overlap reconstruction from two proteases, with a disulfide complication. A 14-residue peptide, cross-linked by one intrachain disulfide bond between two cysteines, gives the following data: Data set 1 — total sequence composition (from acid hydrolysis, order unknown): 2 Cys, 2 Gly, 1 Ala, 1 Lys, 1 Arg, 1 Pro, 2 Ser, 1 Leu, 1 Phe, 1 Tyr, 1 Val. Data set 2 — tryptic digest (after reduction with DTT and alkylation with iodoacetamide to cap free thiols, preventing disulfide reformation and scrambling) gives three fragments by Edman sequencing:
Data set 3 — chymotryptic digest (cleaves after aromatic residues Phe/Tyr/Trp) of the same reduced, alkylated peptide gives two overlapping fragments:
Step 1 — Order the tryptic fragments using chymotryptic overlaps. C1 (Cys–Gly–Phe) matches the start of T1 (Cys–Gly–Phe–Tyr–Arg) exactly, confirming T1 begins the sequence. C2 begins with Tyr–Arg, which is the remainder of T1 after removing the C1 portion, then continues Ser–Pro–Lys (= T2 exactly) then Gly–Val–Ala–Cys(cam)–Leu–Ser (= T3 exactly). This fixes the unique order:
Step 2 — Assemble the full sequence.
Fourteen residues, matching composition exactly (2 Cys ✓, 2 Gly ✓, 1 Ala ✓, 1 Lys ✓, 1 Arg ✓, 1 Pro ✓, 2 Ser ✓, 1 Leu ✓, 1 Phe ✓, 1 Tyr ✓, 1 Val ✓).
Step 3 — Restore disulfide connectivity information (lost by reduction/alkylation). Since reduction destroyed the disulfide before sequencing, the linear order is now known but not which Cys paired with which in the native molecule — trivial here since there are only two Cys (position 1 and position 12), so the single disulfide must be Cys1–Cys12, forming a large macrocyclic loop encompassing the entire chain except the terminal Ser. In a peptide with more than two cysteines this connectivity would require a separate non-reducing/reducing comparison (see below) because sequencing after reduction erases pairing information irretrievably.
Limiting case check: if trypsin alone had been used, the three fragments T1/T2/T3 would give their internal sequences correctly but their order relative to each other would be undetermined — exactly the ambiguity that a second protease with different specificity resolves by overlapping the cut sites, which is precisely why Sanger needed both pepsin and trypsin (among others) digests of insulin, not just one.
Limiting cases, scope & common traps
| Situation | What happens | Correct handling |
|---|---|---|
| N-terminus chemically blocked (acetylated, pyroglutamate, formylated) | Edman degradation gives no PTH signal from cycle 1 onward | Use MS/MS (doesn't require free N-terminus) or enzymatic deblocking (pyroglutamate aminopeptidase) |
| Cleavage site Lys/Arg immediately followed by Pro | Trypsin does not cleave; fragment is longer than "expected" | Always check the residue after each Lys/Arg before predicting fragments |
| Two or more Cys residues, disulfide-linked | Reduction erases which Cys paired with which | Compare non-reducing vs. reducing SDS-PAGE/MS, or partial reduction with fragment mapping, before full reduction |
| Leu vs Ile discrimination by mass | Identical monoisotopic mass (113.084 Da) — MS/MS cannot distinguish by mass alone | Requires immonium ion secondary fragmentation patterns, Edman PTH chromatography, or chemical derivatization |
| Gln vs Lys discrimination | Only 0.036 Da apart | Requires high-resolution/high-accuracy mass spectrometry (FT-ICR, Orbitrap) |
| Deamidation (Asn→Asp, Gln→Glu) during sample prep | Mass increases by 0.984 Da; can mimic a genuine sequence difference | Control pH/temperature during digestion; recognize the characteristic +1 Da-ish mass shift |
| Very long peptide (>60 residues) for Edman | Cumulative incomplete coupling degrades signal-to-noise past ~30-60 cycles | Fragment first with a protease before Edman sequencing |
| Peptide charge state ambiguity in ESI-MS | Same peptide gives multiple m/z peaks (different z) | Deconvolute using the charge-state envelope before mass assignment |
The chemist behind it
Frederick Sanger (1918–2013) trained in biochemistry at Cambridge and spent his career solving problems others considered intractable by inventing new chemistry to solve them — twice earning the Nobel Prize in Chemistry, first in 1958 for sequencing insulin and again in 1980 for DNA sequencing methods. Before Sanger's insulin work, it was not even settled that proteins had a single, defined amino acid sequence rather than some statistical or heterogeneous composition; Sanger's stepwise chemical degradation, using his own reagent 1-fluoro-2,4-dinitrobenzene (Sanger's reagent, "DNFB" or "Sanger's reagent") to tag the N-terminus before acid hydrolysis and chromatographic identification of the labeled residue, gave the first unambiguous proof that a protein sequence was a fixed, ordered chemical structure — the essential experimental foundation beneath the entire central dogma that would soon follow. Sanger split insulin's two chains (A and B, joined by disulfides) apart with performic acid oxidation, degraded each chain's fragments (from partial acid hydrolysis and later enzymatic digestion) by his DNFB method, and used overlapping fragment reads to reconstruct order — precisely the overlap logic still taught today, though automated Edman sequenators (developed by Pehr Edman himself in the 1950s–60s, refined into commercial spinning-cup and gas-phase sequenators by the 1970s) replaced Sanger's original DNFB approach for routine N-terminal sequencing because Edman chemistry, unlike DNFB tagging, does not destroy the peptide after each residue is read.
Origins · 1 minPehr Victor Edman and how this was discovered
Edman recognized that Sanger's DNFB method, while historically decisive, destroyed the peptide with every identification — each read consumed the sample and could only ever answer "what is the N-terminal residue," never "what is the sequence." Edman's insight, publishing his method in 1950 and refining it through the following decade, was to find a labeling chemistry (phenyl isothiocyanate) whose acid-catalyzed cyclization cleaved selectively at the first peptide bond while leaving the shortened chain intact, enabling the same peptide to be read again and again, cycle after cycle. Working through the 1960s with Geoffrey Begg, Edman built the first automated "sequenator," using a rotating cup and programmed reagent delivery to make the method practical for gram quantities of protein — a device whose descendants (fully automated gas-phase and pulsed-liquid sequenators) remained the standard N-terminal sequencing tool in protein chemistry laboratories for the next four decades, until largely superseded by mass spectrometry for routine large-scale work.
Why can't Edman degradation just be applied directly to an intact 300-residue protein?
It can be started on an intact protein, but practical signal degrades severely well before residue 60, because each cycle's coupling, cleavage, and extraction steps are never 100% efficient — typical per-cycle yields are around 98–99% even under optimized automated conditions. Over many cycles, the fraction of molecules that have completed every prior step correctly falls off geometrically (0.98ⁿ), so by cycle 50–60 the correctly-degrading population is swamped by "lagging" sequences that missed a cycle earlier and are now one residue behind, creating a mixed, unreadable signal. This is precisely why large proteins are first cut into fragments of 20–40 residues by a specific protease before Edman sequencing, keeping the read well within the reliable window.
How does mass spectrometry distinguish leucine from isoleucine if they have identical mass?
Standard low-energy CID fragmentation cannot distinguish Leu (residue mass 113.08406 Da) from Ile (also 113.08406 Da, an exact isomer) because b/y ion masses depend only on total residue mass, not connectivity. Distinguishing them requires either higher-energy fragmentation techniques that produce diagnostic side-chain (d- and w-type) ions sensitive to branching pattern, Edman degradation with PTH-standard chromatographic comparison (Leu and Ile PTH-derivatives have distinct retention times), or comparison against a genome-derived database that already specifies which residue should be present at that position.
What is the practical difference between "top-down" and "bottom-up" mass spectrometry proteomics?
Bottom-up proteomics digests the protein with a protease (usually trypsin) first, then analyzes the resulting peptide mixture by LC-MS/MS — it is robust, sensitive, and works for complex mixtures of thousands of proteins, but it scatters any given protein's post-translational modifications across many separate peptides, making it hard to know which modifications co-occur on the same intact molecule. Top-down proteomics instead ionizes and fragments the intact protein directly, preserving the full combination of modifications on a single molecule (a "proteoform") at the cost of requiring higher-resolution instruments and generally working best on purified or simplified samples rather than whole-cell lysates.
Why does the trypsin/Pro exception exist mechanistically, rather than just being an empirical rule?
Serine protease catalysis proceeds through a tetrahedral intermediate at the scissile carbonyl carbon, which must collapse by expelling the leaving-group nitrogen as a good leaving group — typically requiring that nitrogen to become protonated or otherwise stabilized as it develops negative character in the transition state. Proline's nitrogen is a secondary amine locked into a five-membered pyrrolidine ring, which restricts its ability to adopt the needed geometry and reduces its capacity to act as an effective leaving group in that collapse step, and its ring also introduces steric strain in the tetrahedral intermediate itself. The net effect is a dramatically reduced (though not always fully zero) rate of hydrolysis at Xaa-Pro bonds across serine proteases generally, not just trypsin.
Can Edman degradation and mass spectrometry sequencing be used together on the same sample?
Yes, and this is common in practice: Edman sequencing of an intact or lightly-digested sample gives unambiguous N-terminal reads (useful for confirming manufacturing consistency of a therapeutic protein or resolving Leu/Ile ambiguity), while parallel LC-MS/MS on a full tryptic digest gives near-complete sequence coverage, quantitative abundance information, and post-translational modification mapping that Edman chemistry alone cannot provide efficiently. The two methods are complementary rather than competing: Edman gives slow but chemically unambiguous positional reads, MS gives fast, high-throughput, modification-sensitive coverage.
Why is reduction with DTT or TCEP followed by alkylation with iodoacetamide standard before proteomic digestion, even for proteins with no cysteines of known functional importance?
Reduction (DTT, dithiothreitol, or TCEP, tris(2-carboxyethyl)phosphine) breaks any disulfide bonds so that individual peptide chains and intrachain loops become linear, avoiding both incorrect fragment mass assignment and physical entanglement of tryptic peptides that would otherwise co-elute or misfold during digestion. Alkylation with iodoacetamide then caps the freed thiols as stable carbamidomethyl-cysteine (adding 57.0215 Da to the residue mass, a standard fixed modification accounted for in database searches), preventing disulfide reformation or thiol-disulfide scrambling during the subsequent digestion and analysis, which would otherwise introduce artifactual heterogeneity into the mass spectrum.
Does overlap reconstruction from two proteases always give a unique sequence, or can ambiguity remain?
For most real proteins, two proteases with sufficiently different and frequent cleavage specificities (trypsin plus chymotrypsin, or trypsin plus Glu-C) generate enough overlapping fragments to fix a unique order, exactly as in the worked disulfide example above. However, ambiguity can persist in regions with few cleavage sites for either enzyme (long fragments with no internal Lys/Arg/aromatic residues), in repetitive sequences where multiple valid orderings satisfy the same overlap pattern, or where a fragment is too short to sequence reliably; in modern practice, these gaps are usually closed by comparing against a genome or cDNA-predicted sequence rather than by exhaustive further wet chemistry.